Matches in SemOpenAlex for { <https://semopenalex.org/work/W2115492058> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W2115492058 endingPage "1633" @default.
- W2115492058 startingPage "1631" @default.
- W2115492058 abstract "Download the Issue @ a Glance podcastSubscribe to the EHJ Podcast ![Graphic][1] Transcatheter mitral interventions have been developed to address an unmet need, and as alternatives to surgery in patients at high risk or considered inoperable.1,2 Beyond MitraClip therapy, alternative repair technologies are being developed to expand the armamentarium of transcatheter intervention. Recently, the feasibility of transcatheter mitral valve implantation in native non-calcified valves was reported in patients at very high operative risk. These issues are critically discussed in a timely Clinical Review article entitled ‘ The future of transcatheter mitral valve interventions: competitive or complementary role of repair vs replacement? ’ by Francesco Maisano from the University Hospital Zurich in Switzerland.3 The authors review the current state-of-the-art of mitral valve intervention, and identify potential future scenarios that might benefit most from the transcatheter repair and replacement devices under development. He also acknowledges the small body of scientific evidence4,5 on hard outcomes during long-term follow-up of these novel procedures.Atrial tachyarrhythmias are often associated with mitral valve disease, but are also frequent in elderly patients without it. As both arrhythmias are associated with a risk of stroke, anticoagulation is considered mandatory in those with a high CHA2DS2VASC score.6,7 In the first research paper entitled ‘ Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices ’, Jonathan L. Halperin from Mount Sinai School of Medicine in New York8 hypothesized that the introduction and termination of anticoagulation based upon arrhythmia monitoring would reduce both stroke … [1]: /embed/inline-graphic-1.gif" @default.
- W2115492058 created "2016-06-24" @default.
- W2115492058 creator A5045293936 @default.
- W2115492058 date "2015-07-07" @default.
- W2115492058 modified "2023-09-23" @default.
- W2115492058 title "Mitral valve disease, atrial fibrillation, and device therapy" @default.
- W2115492058 cites W1970242617 @default.
- W2115492058 cites W1978759006 @default.
- W2115492058 cites W2003607193 @default.
- W2115492058 cites W2018892686 @default.
- W2115492058 cites W2082420696 @default.
- W2115492058 cites W2084887154 @default.
- W2115492058 cites W2092980394 @default.
- W2115492058 cites W2112988131 @default.
- W2115492058 cites W2113779990 @default.
- W2115492058 cites W2115263501 @default.
- W2115492058 cites W2116416278 @default.
- W2115492058 cites W2118413289 @default.
- W2115492058 cites W2144231356 @default.
- W2115492058 cites W2148795889 @default.
- W2115492058 cites W2159672645 @default.
- W2115492058 cites W2166679677 @default.
- W2115492058 cites W2313180692 @default.
- W2115492058 cites W2320196710 @default.
- W2115492058 cites W2329248763 @default.
- W2115492058 cites W2332023409 @default.
- W2115492058 doi "https://doi.org/10.1093/eurheartj/ehv225" @default.
- W2115492058 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26152588" @default.
- W2115492058 hasPublicationYear "2015" @default.
- W2115492058 type Work @default.
- W2115492058 sameAs 2115492058 @default.
- W2115492058 citedByCount "1" @default.
- W2115492058 countsByYear W21154920582019 @default.
- W2115492058 crossrefType "journal-article" @default.
- W2115492058 hasAuthorship W2115492058A5045293936 @default.
- W2115492058 hasBestOaLocation W21154920581 @default.
- W2115492058 hasConcept C126322002 @default.
- W2115492058 hasConcept C164705383 @default.
- W2115492058 hasConcept C2777543888 @default.
- W2115492058 hasConcept C2779161974 @default.
- W2115492058 hasConcept C71924100 @default.
- W2115492058 hasConceptScore W2115492058C126322002 @default.
- W2115492058 hasConceptScore W2115492058C164705383 @default.
- W2115492058 hasConceptScore W2115492058C2777543888 @default.
- W2115492058 hasConceptScore W2115492058C2779161974 @default.
- W2115492058 hasConceptScore W2115492058C71924100 @default.
- W2115492058 hasIssue "26" @default.
- W2115492058 hasLocation W21154920581 @default.
- W2115492058 hasLocation W21154920582 @default.
- W2115492058 hasOpenAccess W2115492058 @default.
- W2115492058 hasPrimaryLocation W21154920581 @default.
- W2115492058 hasRelatedWork W1971668985 @default.
- W2115492058 hasRelatedWork W2051866166 @default.
- W2115492058 hasRelatedWork W2096143604 @default.
- W2115492058 hasRelatedWork W2350497074 @default.
- W2115492058 hasRelatedWork W2350797668 @default.
- W2115492058 hasRelatedWork W2390053719 @default.
- W2115492058 hasRelatedWork W2409706576 @default.
- W2115492058 hasRelatedWork W2412400196 @default.
- W2115492058 hasRelatedWork W2413821920 @default.
- W2115492058 hasRelatedWork W762865 @default.
- W2115492058 hasVolume "36" @default.
- W2115492058 isParatext "false" @default.
- W2115492058 isRetracted "false" @default.
- W2115492058 magId "2115492058" @default.
- W2115492058 workType "article" @default.
!["Download the Issue @ a Glance podcastSubscribe to the EHJ Podcast ![Graphic][1] Transcatheter mitral interventions have been developed to address an unmet need, and as alternatives to surgery in patients at high risk or considered inoperable.1,2 Beyond MitraClip therapy, alternative repair technologies are being developed to expand the armamentarium of transcatheter intervention. Recently, the feasibility of transcatheter mitral valve implantation in native non-calcified valves was reported in patients at very high operative risk. These issues are critically discussed in a timely Clinical Review article entitled ‘ The future of transcatheter mitral valve interventions: competitive or complementary role of repair vs replacement? ’ by Francesco Maisano from the University Hospital Zurich in Switzerland.3 The authors review the current state-of-the-art of mitral valve intervention, and identify potential future scenarios that might benefit most from the transcatheter repair and replacement devices under development. He also acknowledges the small body of scientific evidence4,5 on hard outcomes during long-term follow-up of these novel procedures.Atrial tachyarrhythmias are often associated with mitral valve disease, but are also frequent in elderly patients without it. As both arrhythmias are associated with a risk of stroke, anticoagulation is considered mandatory in those with a high CHA2DS2VASC score.6,7 In the first research paper entitled ‘ Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices ’, Jonathan L. Halperin from Mount Sinai School of Medicine in New York8 hypothesized that the introduction and termination of anticoagulation based upon arrhythmia monitoring would reduce both stroke … [1]: /embed/inline-graphic-1.gif"](?object=%22Download%20the%20Issue%20%40%20a%20Glance%20podcastSubscribe%20to%20the%20EHJ%20Podcast%20!%5BGraphic%5D%5B1%5D%20Transcatheter%20mitral%20interventions%20have%20been%20developed%20to%20address%20an%20unmet%20need%2C%20and%20as%20alternatives%20to%20surgery%20in%20patients%20at%20high%20risk%20or%20considered%20inoperable.1%2C2%20Beyond%20MitraClip%20therapy%2C%20alternative%20repair%20technologies%20are%20being%20developed%20to%20expand%20the%20armamentarium%20of%20transcatheter%20intervention.%20Recently%2C%20the%20feasibility%20of%20transcatheter%20mitral%20valve%20implantation%20in%20native%20non-calcified%20valves%20was%20reported%20in%20patients%20at%20very%20high%20operative%20risk.%20These%20issues%20are%20critically%20discussed%20in%20a%20timely%20Clinical%20Review%20article%20entitled%20%E2%80%98%20The%20future%20of%20transcatheter%20mitral%20valve%20interventions%3A%20competitive%20or%20complementary%20role%20of%20repair%20vs%20replacement%3F%20%E2%80%99%20by%20Francesco%20Maisano%20from%20the%20University%20Hospital%20Zurich%20in%20Switzerland.3%20The%20authors%20review%20the%20current%20state-of-the-art%20of%20mitral%20valve%20intervention%2C%20and%20identify%20potential%20future%20scenarios%20that%20might%20benefit%20most%20from%20the%20transcatheter%20repair%20and%20replacement%20devices%20under%20development.%20He%20also%20acknowledges%20the%20small%20body%20of%20scientific%20evidence4%2C5%20on%20hard%20outcomes%20during%20long-term%20follow-up%20of%20these%20novel%20procedures.Atrial%20tachyarrhythmias%20are%20often%20associated%20with%20mitral%20valve%20disease%2C%20but%20are%20also%20frequent%20in%20elderly%20patients%20without%20it.%20As%20both%20arrhythmias%20are%20associated%20with%20a%20risk%20of%20stroke%2C%20anticoagulation%20is%20considered%20mandatory%20in%20those%20with%20a%20high%20CHA2DS2VASC%20score.6%2C7%20In%20the%20first%20research%20paper%20entitled%20%E2%80%98%20Randomized%20trial%20of%20atrial%20arrhythmia%20monitoring%20to%20guide%20anticoagulation%20in%20patients%20with%20implanted%20defibrillator%20and%20cardiac%20resynchronization%20devices%20%E2%80%99%2C%20Jonathan%20L.%20Halperin%20from%20Mount%20Sinai%20School%20of%20Medicine%20in%20New%20York8%20hypothesized%20that%20the%20introduction%20and%20termination%20of%20anticoagulation%20based%20upon%20arrhythmia%20monitoring%20would%20reduce%20both%20stroke%20%E2%80%A6%20%5B1%5D%3A%20%2Fembed%2Finline-graphic-1.gif%22){kind=link}